Ocular Therapeutix, Inc. (OCUL)

NASDAQ: OCUL · IEX Real-Time Price · USD
5.75
+0.71 (14.09%)
At close: Jun 14, 2024, 4:00 PM
5.81
+0.06 (1.04%)
After-hours: Jun 14, 2024, 7:59 PM EDT
14.09%
Market Cap 890.61M
Revenue (ttm) 59.84M
Net Income (ttm) -115.27M
Shares Out 154.89M
EPS (ttm) -1.25
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,714,359
Open 5.15
Previous Close 5.04
Day's Range 5.11 - 6.08
52-Week Range 2.00 - 11.31
Beta 1.42
Analysts Buy
Price Target 15.17 (+163.83%)
Earnings Date Aug 5, 2024

About OCUL

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 25, 2014
Employees 267
Stock Exchange NASDAQ
Ticker Symbol OCUL
Full Company Profile

Financial Performance

In 2023, OCUL's revenue was $58.44 million, an increase of 13.49% compared to the previous year's $51.49 million. Losses were -$80.74 million, 13.7% more than in 2022.

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for OCUL stock is "Buy." The 12-month stock price forecast is $15.17, which is an increase of 163.83% from the latest price.

Price Target
$15.17
(163.83% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR Study

151 subjects enrolled in various stages of loading and randomization in SOL-1 pivotal study of AXPAXLI in wet AMD as of June 7, 2024

1 day ago - GlobeNewsWire

Ocular Therapeutix® to Host Investor Day on June 13, 2024

Company to highlight corporate strategy, clinical data, and development plans for AXPAXLI™  in wet AMD and NPDR

10 days ago - GlobeNewsWire

Ocular Therapeutix® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people's vision and quality of life through the ...

10 days ago - GlobeNewsWire

Ocular Therapeutix™ Reports First Quarter 2024 Results

Recent Leadership Appointments Put Ocular on Track to Become a Leader in Retinal Care Site Activation and Patient Enrollment for AXPAXLI™ SOL-1 Phase 3 wet AMD Trial Progressing with First Subjects Ra...

5 weeks ago - GlobeNewsWire

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people's vision and quality of life through the d...

5 weeks ago - GlobeNewsWire

Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences

BEDFORD, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people's vision and quality of life...

5 weeks ago - GlobeNewsWire

Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024

2024 OIS Retina and ARVO meetings are being held in Seattle, Washington 2024 OIS Retina and ARVO meetings are being held in Seattle, Washington

6 weeks ago - GlobeNewsWire

Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024

First quarter 2024 financial results to be reported on Tuesday, May 7, 2024 Investor Day to replace first quarter 2024 earnings conference call; quarterly calls to resume regular cadence with second q...

6 weeks ago - GlobeNewsWire

Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy

46.2% of patients demonstrated a 1- or 2-step improvement in the Diabetic Retinopathy Severity Scale (DRSS) at 40 weeks in the AXPAXLI arm, compared to 0% in the control arm

2 months ago - GlobeNewsWire

Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO

BEDFORD, Mass., April 15, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people's vision and quality of life through the...

2 months ago - GlobeNewsWire

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics

BEDFORD, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people's vision and quality of life through the...

2 months ago - GlobeNewsWire

Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting

Phase 2 data highlight consistent and sustained reductions in Intraocular Pressure (IOP), statistically significant (p

2 months ago - GlobeNewsWire

Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)

BEDFORD, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people's vision and quality of li...

2 months ago - GlobeNewsWire

Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results

Leadership Appointments Move Ocular Towards Being a Leader in Retinal Care Screening Underway in AXPAXLI™ Phase 3 SOL-1 Trial for Wet AMD Topline Clinical Data for AXPAXLI in Diabetic Retinopathy and ...

3 months ago - GlobeNewsWire

Ocular Therapeutix™ to Release Fourth Quarter and Full Year 2023 Results on March 11, 2024

BEDFORD, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, the “Company”), a biopharmaceutical company committed to enhancing people's vision and quality of life through...

3 months ago - GlobeNewsWire

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Chairman and Chief Strategy Officer

BEDFORD, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people's vision and quality of life through the ...

4 months ago - GlobeNewsWire

Ocular Therapeutix, Inc. Announces $325.0 Million Private Placement

BEDFORD, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (Nasdaq:OCUL) (the “Company”), a biopharmaceutical company committed to enhancing people's vision and quality of life through...

4 months ago - GlobeNewsWire

Ocular Therapeutix™ Announces Board of Directors and Leadership Updates

Industry Leader and Retina Expert, Pravin U. Dugel, MD, Becomes Executive Chair Jeffrey S.

4 months ago - GlobeNewsWire

AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA® for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic Conjunctivitis

SHANGHAI , Feb. 19, 2024 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a biotechnology company dedicated to developing and commercializing transformative pharmaceutical, and surgical products that...

4 months ago - PRNewsWire

Ocular Therapeutix™ Appoints Steve Meyers to Chief Commercial Officer

Strategic promotion underscores commitment to commercial growth across Ocular portfolio Strategic promotion underscores commitment to commercial growth across Ocular portfolio

4 months ago - GlobeNewsWire

Ocular Therapeutix™ Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of AXPAXLI™ in Wet AMD

Phase 3 SOL-1 study will evaluate the efficacy and safety of AXPAXLI in wet AMD Phase 3 SOL-1 study will evaluate the efficacy and safety of AXPAXLI in wet AMD

4 months ago - GlobeNewsWire

Ocular Therapeutix™ Announces FDA Agreement to Amend Special Protocol Assessment (SPA) for Pivotal Clinical Trial of AXPAXLI™ in Wet AMD

SPA amendment expands eligibility criteria for SOL clinical trial Broadening of eligibility criteria anticipated to accelerate overall trial enrollment BEDFORD, Mass., Jan. 25, 2024 (GLOBE NEWSWIRE) -...

5 months ago - GlobeNewsWire

Ocular Therapeutix™ Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

BEDFORD, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix™, Inc. (Nasdaq: OCUL) (the “Company”), a biopharmaceutical company focused on the formulation, development, and commercialization o...

6 months ago - GlobeNewsWire

Ocular Therapeutix™ Announces Pricing of Public Offering of Common Stock

BEDFORD, Mass., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix™, Inc. (Nasdaq: OCUL) (the “Company”), a biopharmaceutical company focused on the formulation, development, and commercialization o...

6 months ago - GlobeNewsWire

Ocular Therapeutix™ Announces Proposed Public Offering of Common Stock

BEDFORD, Mass., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix™, Inc. (Nasdaq: OCUL) (the “Company”), a biopharmaceutical company focused on the formulation, development, and commercialization o...

6 months ago - GlobeNewsWire